Rationale and design of a randomized trial evaluating an external support device for saphenous vein coronary grafts - 07/03/22
, John D. Puskas, MD b, Alan J. Moskowitz, MD a, Annetine C. Gelijns, PhD a, John H. Alexander, MD c, Jagat Narula, PhD d, Peter K. Smith, MD c, Kelley Hutcheson, MD e, Helena L. Chang, MS a, James S. Gammie, MD f, Alexander Iribarne, MD g, Mary E. Marks, BSN a, Yuliya Vengrenyuk, PhD h, Keisuke Yasumura, MD h, Samantha Raymond, MPH a, Bradley S. Taylor, MD i, Orit Yarden, PhD j, Eyal Orion, MD j, François Dagenais, MD k, Gorav Ailawadi, MD l, Michael W.A. Chu, MD m, Lopa Gupta, MPH a, Ronald G. Levitan, MSc a, Judson B. Williams, MD n, Juan A. Crestanello, MD o, Mariell Jessup, MD p, Eric A. Rose, MD a, Vincent Scavo, MD q, Michael A. Acker, MD r, Marc Gillinov, MD s, Patrick T. O'Gara, MD t, Pierre Voisine, MD k, Michael J. Mack, MD e, Daniel J. Goldstein, MD uRésumé |
Background |
Coronary artery bypass grafting (CABG) is the most common revascularization approach for the treatment of multi-vessel coronary artery disease. While the internal mammary artery is nearly universally used to bypass the left anterior descending coronary artery, autologous saphenous vein grafts (SVGs) are still the most frequently used conduits to grafts the remaining coronary artery targets. Long-term failure of these grafts, however, continues to limit the benefits of surgery.
Methods |
The Cardiothoracic Surgical Trials Network trial of the safety and effectiveness of a Venous External Support (VEST) device is a randomized, multicenter, within-patient trial comparing VEST-supported versus unsupported saphenous vein grafts in patients undergoing CABG. Key inclusion criteria are the need for CABG with a planned internal mammary artery to the left anterior descending and two or more saphenous vein grafts to other coronary arteries. The primary efficacy endpoint of the trial is SVG intimal hyperplasia (plaque + media) area assessed by intravascular ultrasound at 12 months post randomization. Occluded grafts are accounted for in the analysis of the primary endpoint. Secondary confirmatory endpoints are lumen diameter uniformity and graft failure (>50% stenosis) assessed by coronary angiography at 12 months. The safety endpoints are the occurrence of major adverse cardiac and cerebrovascular events and hospitalization within 5 years from randomization.
Conclusions |
The results of the VEST trial will determine whether the VEST device can safely limit SVG intimal hyperplasia in patients undergoing CABG as treatment for coronary atherosclerotic disease.
Le texte complet de cet article est disponible en PDF.Plan
| This paper was handled by Guest Editor (Charles Maynard, PhD) |
Vol 246
P. 12-20 - avril 2022 Retour au numéro
Article précédent
- Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions — proceedings from the CEC Summit 2018
- Abhinav Sharma, Kenneth W. Mahaffey, Charles Michael Gibson, Karen A. Hicks, Karen P. Alexander, Maria Ali, Bernard R. Chaitman, Claes Held, Mark Hlatky, WIlliam Schuyler Jones, Roxana Mehran, Venu Menon, Frank W. Rockhold, Jonathan Seltzer, Ernest Spitzer, Matthew Wilson, Renato D. Lopes
- Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design
- Hironori Hara, Patrick W. Serruys, Neil O'Leary, Chao Gao, Alicia Murray, Elaine Breslin, Scot Garg, Christophe Bureau, Johan HC Reiber, Emanuele Barbato, Adel Aminian, Luc Janssens, Liesbeth Rosseel, Edouard Benit, Gianluca Campo, Vincenzo Guiducci, Gianni Casella, Andrea Santarelli, Alfonso Franzè, Victor Alfonso Jimenez Diaz, Andrés Iñiguez, Salvatore Brugaletta, Manel Sabate, Ignacio J. Amat-Santos, Giovanni Amoroso, Joanna Wykrzykowska, Clemens von Birgelen, Samer Somi, Tommy Liu, Sjoerd H. Hofma, Nick Curzen, Ramiro Trillo, Raymundo Ocaranza, Anthony Mathur, Pieter C. Smits, Javier Escaned, Andreas Baumbach, William Wijns, Faisal Sharif, Yoshinobu Onuma, PIONEER IV trial investigator
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?